Armata Pharmaceuticals announced data demonstrating that controlled genetic diversity in its AP-SA02 bacteriophage cocktail enhances its ability to kill methicillin-sensitive and methicillin-resistant Staphylococcus aureus (MSSA and MRSA) clinical isolates. This diversity is deliberately maintained through controlled manufacturing to improve treatment performance. Positive Phase 2a trial results showed 100% clinical response in treated patients, supporting advancement to a Phase 3 study for complicated S. aureus bacteremia. Findings were presented at the 2026 International Symposium on Staphylococci and Staphylococcal Infections.
Armata Pharmaceuticals' data presentation on genetic diversity in its AP-SA02 bacteriophage cocktail is the subject, with Pluang market data as context. As of Sep 21, 2026 17:21 WIB, among 92 priced Health-sector US stocks tradable on Pluang, 46 rose and 29 fell. Notable movers include TWST at USD 171.98 with a +2.99% change, DNA at USD 8.04 with +2.03%, and MRNA at USD 157.09 with +1.98%.
Canary Capital has filed an amendment to its S-1 registration for a Staked SEI ETF, now planning to stake about 90% of the ETF's SEI holdings. BitGo will serve as the sole custodian for the entire staked position, and the ETF will trade on Cboe BZX. ...
Lititz Mutual Insurance has implemented Guidewire's ProNavigator, an embedded AI assistant, to provide employees and independent agents with instant, accurate answers from company policies during underwriting and claims processes. This AI tool aims t...
Sui (SUI) experienced a significant single-day price increase on September 21, 2026, despite no verified announcements from Mysten Labs or the Sui Foundation explaining the surge. Market data shows no confirmed partnership, product launch, or token u...
Hormel Foods has maintained its impressive 60-year streak of consecutive dividend increases, recently raising its dividend by just 1% to $1.17 per share annually. While this continues the company's legacy as a Dividend King, the modest raise barely k...
The Federal Reserve raised interest rates in September, marking a shift in pace under FOMC Chair Warsh and suggesting more hikes may follow. This move responds to persistent inflation and inflation expectations, which are likely to keep pressure on t...
